Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of...

Related Keywords

United Kingdom ,Israel ,Italy ,Milan ,Lombardia ,Rebecca Ross ,Hilit Levi ,Ilan Vaknin ,Irina Koffler ,Wadi Mor ,Barbara Lindheim ,Prnewswire Chemomab Therapeutics Ltd ,Strategic Communications ,European Congress ,Lifesci Advisors ,Nasdaq ,Leeds Institute Of Rheumatic ,Chemomab Therapeutics Ltd ,University Of Leeds ,European Alliance Of Association ,New Patient Data Further Implicates ,Fibrotic Disease Pathology ,Neutralizing Antibody ,Systemic Sclerosis ,European Alliance ,Italy May ,Professor Enrico De Lorenzis ,Leeds Institute ,Musculoskeletal Diseases ,Professor De Lorenzis ,Chief Scientific Officer ,Enrico De Lorenzis ,Stefano Di Donato ,Revital Aricha ,Francesco Del Galdo ,Private Securities Litigation Reform ,Sci Advisors ,Vice President ,Chemomab Therapeutics ,Td ,